A disruptive technology to tackle brain cancer and glioblastoma
News
American Association of Neurological Surgeons (AANS) Annual Meeting: Hemerion Gains Momentum in the U.S.
Hemerion’s participation in the American Association of Neurological Surgeons (AANS) Annual Meeting from May 1 to 4, 2026, allowed our team to strengthen ties with international clinicians and showcase its… ...
Boston Mission: Hemerion Engages with the U.S. Healthtech Ecosystem
Upon returning from the annual meeting of the American Association of Neurological Surgeons (AANS) held in San Diego, Hemerion continued its expansion into the U.S. market. Maximilien Vermandel and Patrick… ...
Hemerion Announces Completion of Patient Enrollment in HTX-GBM01 Trial and Accelerates Clinical Development of its Lead Therapy
The latest Independent Data and Safety Monitoring Board (iDSMB) meeting confirmed that Hemerion completed patient enrollment in its HTX-GBM-01 clinical trial of the Pentalafen/Heliance therapy for the treatment of glioblastoma.… ...
Stay tuned to our clinical advances
They talk about us
